Bank of New York Mellon’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-183,012
| Closed | -$1.67M | – | 4252 |
|
|
2025
Q2 | $1.67M | Buy |
183,012
+10,281
| +6% | +$75.6K | ﹤0.01% | 2838 |
|
|
2025
Q1 | $1.37M | Buy |
172,731
+1,287
| +0.8% | +$9.42K | ﹤0.01% | 2870 |
|
|
2024
Q4 | $931K | Sell |
171,444
-9,655
| -5% | -$59K | ﹤0.01% | 3208 |
|
|
2024
Q3 | $1.31M | Sell |
181,099
-37,647
| -17% | -$345K | ﹤0.01% | 2987 |
|
|
2024
Q2 | $2.38M | Buy |
218,746
+37,691
| +21% | +$483K | ﹤0.01% | 2699 |
|
|
2024
Q1 | $3.39M | Sell |
181,055
-14,758
| -8% | -$340K | ﹤0.01% | 2504 |
|
|
2023
Q4 | $4.24M | Sell |
195,813
-37,576
| -16% | -$745K | ﹤0.01% | 2456 |
|
|
2023
Q3 | $4.8M | Sell |
233,389
-2,279
| -1% | -$65.8K | ﹤0.01% | 2340 |
|
|
2023
Q2 | $11.1M | Sell |
235,668
-13,580
| -5% | -$676K | ﹤0.01% | 1902 |
|
|
2023
Q1 | $10.5M | Sell |
249,248
-334
| -0.1% | -$14.4K | ﹤0.01% | 1919 |
|
|
2022
Q4 | $9.52M | Sell |
249,582
-114,547
| -31% | -$4.37M | ﹤0.01% | 1969 |
|
|
2022
Q3 | $14.3M | Buy |
364,129
+12,345
| +4% | +$477K | ﹤0.01% | 1686 |
|
|
2022
Q2 | $11.4M | Sell |
351,784
-839
| -0.2% | -$28.1K | ﹤0.01% | 1861 |
|
|
2022
Q1 | $11.7M | Buy |
352,623
+10,134
| +3% | +$381K | ﹤0.01% | 1979 |
|
|
2021
Q4 | $14.6M | Buy |
342,489
+89,406
| +35% | +$3.74M | ﹤0.01% | 1899 |
|
|
2021
Q3 | $11.2M | Sell |
253,083
-21,570
| -8% | -$989K | ﹤0.01% | 2056 |
|
|
2021
Q2 | $15.6M | Buy |
274,653
+75,491
| +38% | +$5.34M | ﹤0.01% | 1874 |
|
|
2021
Q1 | $14.9M | Sell |
199,162
-8,045
| -4% | -$660K | ﹤0.01% | 1873 |
|
|
2020
Q4 | $17.9M | Buy |
207,207
+3,497
| +2% | +$258K | ﹤0.01% | 1704 |
|
|
2020
Q3 | $12.4M | Sell |
203,710
-3,190
| -2% | -$162K | ﹤0.01% | 1731 |
|
|
2020
Q2 | $8.6M | Sell |
206,900
-1,218
| -0.6% | -$44.2K | ﹤0.01% | 1921 |
|
|
2020
Q1 | $5.98M | Sell |
208,118
-327,485
| -61% | -$19M | ﹤0.01% | 1989 |
|
|
2019
Q4 | $38.7M | Sell |
535,603
-417,750
| -44% | -$51.4M | 0.01% | 1150 |
|
|
2019
Q3 | $134M | Sell |
953,353
-238,650
| -20% | -$39.9M | 0.04% | 442 |
|
|
2019
Q2 | $218M | Sell |
1,192,003
-270,622
| -19% | -$46.2M | 0.06% | 297 |
|
|
2019
Q1 | $233M | Sell |
1,462,625
-368,812
| -20% | -$53.4M | 0.07% | 281 |
|
|
2018
Q4 | $175M | Buy |
1,831,437
+283,077
| +18% | +$32.4M | 0.05% | 327 |
|
|
2018
Q3 | $219M | Sell |
1,548,360
-16,188
| -1% | -$2.5M | 0.06% | 323 |
|
|
2018
Q2 | $245M | Buy |
1,564,548
+110,134
| +8% | +$17.3M | 0.07% | 289 |
|
|
2018
Q1 | $234M | Sell |
1,454,414
-166,197
| -10% | -$28.2M | 0.06% | 304 |
|
|
2017
Q4 | $267M | Sell |
1,620,611
-1,089,416
| -40% | -$106M | 0.07% | 290 |
|
|
2017
Q3 | $169M | Buy |
2,710,027
+724,494
| +36% | +$56.9M | 0.05% | 397 |
|
|
2017
Q2 | $158M | Sell |
1,985,533
-71,362
| -3% | -$5.16M | 0.04% | 412 |
|
|
2017
Q1 | $146M | Buy |
2,056,895
+1,345,829
| +189% | +$78.8M | 0.04% | 445 |
|
|
2016
Q4 | $36.3M | Buy |
711,066
+573,799
| +418% | +$27M | 0.01% | 1152 |
|
|
2016
Q3 | $6.32M | Buy |
137,267
+33,257
| +32% | +$1.35M | ﹤0.01% | 2122 |
|
|
2016
Q2 | $3.13M | Buy |
104,010
+11,978
| +13% | +$399K | ﹤0.01% | 2462 |
|
|
2016
Q1 | $2.95M | Sell |
92,032
-218,795
| -70% | -$7.7M | ﹤0.01% | 2439 |
|
|
2015
Q4 | $18.1M | Buy |
310,827
+227,719
| +274% | +$11.3M | 0.01% | 1456 |
|
|
2015
Q3 | $3.52M | Sell |
83,108
-5,857
| -7% | -$361K | ﹤0.01% | 2422 |
|
|
2015
Q2 | $6.5M | Buy |
88,965
+51,353
| +137% | +$3.3M | ﹤0.01% | 2202 |
|
|
2015
Q1 | $1.89M | Sell |
37,612
-1,921
| -5% | -$82.6K | ﹤0.01% | 2909 |
|
|
2014
Q4 | $1.45M | Buy |
39,533
+10,938
| +38% | +$408K | ﹤0.01% | 3067 |
|
|
2014
Q3 | $901K | Buy |
+28,595
| New | +$829K | ﹤0.01% | 3351 |
|
Other funds holding SAGE
IA
HNB
Bank of New York Mellon's SAGE Position: Q3 2025 in Review
Bank of New York Mellon sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 183,012 shares — an estimated $1.67M sold.
Bank of New York Mellon first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $267M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Bank of New York Mellon reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Bank of New York Mellon sold 183,012 Sage Therapeutics shares in Q3 2025, an estimated $1.67M.
- Bank of New York Mellon first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
- Bank of New York Mellon's Sage Therapeutics position peaked at $267M in Q4 2017.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.